It is a very exciting day for the PMS community: FDA has cleared Jaguar's JAG201 for Phase 1 clinical trials! JAG201 is a gene therapy addressing SHANK3 deletions and variants, which cause Phelan-McDermid syndrome.

Abby Lievense inspires with her story of resilience and dedication to her son, Darus.

We are excited to share the announcement of our first gene-based therapeutic program for Phelan-McDermid syndrome!

CureSHANK is a proud member of COMBINEDbrain a non-profit consortium of 25 patient-advocacy groups, each representing a different rare genetic neurodevelopmental disorder.

Daria - the daughter of CureSHANK’s co-founder Paulina Rychenkova, - is officially a teenager today!

We’re excited to announce the launch of CureSHANK’s two signature programs to address the major gap areas in drug development for Phelan-McDermid Syndrome: